SPEAR UltraDetect™ pTau217 Biomarker Assay Kit
The SPEAR UltraDetect™ pTau 217 biomarker assay kit provides a highly specific tool for Alzheimer’s disease research, optimized for plasma samples. Requires SPEAR UltraDetect™ Reaction Kit. For research use only.
Receive your quote directly from the manufacturer.
A breakthrough blood biomarker for AD pathology
pTau 217 (phosphorylated tau at threonine 217) is a highly specific blood-based biomarker of brain amyloid βpathology. Validated against PET imaging and CSF Aβ42/40, it has demonstrated high sensitivity and specificity for identifying amyloid positivity, often outperforming other plasma markers such as pTau181 or Aβ42/40. These properties make pTau 217 it a valuable tool for early detection, noninvasive screening, and disease tracking in diagnostic research, therapeutic trials, and longitudinal studies for AD.
Unparalleled Specificity with SPEAR UltraDetect pTau 217
The SPEAR UltraDetect pTau 217 assay has demonstrated unparalleled specificity in differentiating Alzheimer’s disease and non-AD patient samples. Combined with its sensitivity and precision (quantifying 100% of healthy samples above fLLOQ), SPEAR UltraDetect pTau 217 offers researchers a powerful tool to better characterize blood based samples in Alzheimer’s research.
In a study to demonstrate SPEAR UltraDetect pTau 217 performance, CSF- and PET-confirmed Alzheimer’s Disease (AD) and non-AD samples were both tested. In this combined cohort study, SPEAR UltraDetect pTau 217 demonstrated a 5.41x mean fold-difference between groups and area under the curve (AUC) of 0.989 for CSF-confirmed samples and 0.984 for PET-confirmed samples.This level of differentiation and predictive power highlights the SPEAR UltraDetect pTau 217 assay in its ability to classify Alzheimer’s and non-Alzheimer’s patientplasma samples.
